Growth Metrics

Pfizer (PFE) Total Current Liabilities (2016 - 2026)

Pfizer has reported Total Current Liabilities over the past 18 years, most recently at $34.3 billion for Q1 2026.

  • Quarterly Total Current Liabilities fell 5.77% to $34.3 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $34.3 billion through Mar 2026, down 5.77% year-over-year, with the annual reading at $37.0 billion for FY2025, 13.98% down from the prior year.
  • Total Current Liabilities was $34.3 billion for Q1 2026 at Pfizer, down from $37.0 billion in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $47.8 billion in Q4 2023 and troughed at $5.2 billion in Q4 2022.
  • The 5-year median for Total Current Liabilities is $37.7 billion (2025), against an average of $37.5 billion.
  • The largest YoY upside for Total Current Liabilities was 494.77% in 2023 against a maximum downside of 26.92% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $42.1 billion in 2022, then grew by 13.42% to $47.8 billion in 2023, then fell by 10.04% to $43.0 billion in 2024, then decreased by 13.98% to $37.0 billion in 2025, then fell by 7.13% to $34.3 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Total Current Liabilities are $34.3 billion (Q1 2026), $37.0 billion (Q4 2025), and $36.6 billion (Q3 2025).